Synvolux Therapeutics B.V. is a privately held biotech company dedicated to the development, production and commercialization of new therapies using its SAINT technology: an unique, safe and highly efficacious delivery technology for macromolecules (DNA, RNA, proteins and others).
Synvolux has a patent portfolio which covers more than 2 million chemical structures. They directly approach large biotech and big pharma with its own sales force. Synvolux Therapeutics' collaborators include: Vivomicx (in the field of targeted siRNA delivery) and The Jackson Laboratory. The company has also entered sub-licensing and other agreements with Qiagen and Mologen.
9713 GX Groningen
T 050 311 81 15
F 0584 210 55 41